Impact of Prognostic Nutritional Index on Terminal Cancer Patients

Faculty Medicine Year: 2020
Type of Publication: ZU Hosted Pages:
Authors:
Journal: Indian J Palliat Care Wolters Kluwer - Medknow Volume:
Keywords : Impact , Prognostic Nutritional Index , Terminal Cancer Patients    
Abstract:
Background: In terminal cancer patients (TCPs), one of the most important things is to define the survival to help the main responsible physicians, patients, and main caregivers make decisions, set goals, and work across the end‑of‑life strategies. Patients and Methods: We retrospectively reviewed the medical files of TCPs, who died during September 2011 and December 2017, to recognize the correlation between prognostic nutritional indices (PNIs) and survival in those subtypes of patients. The receiver operating characteristic (ROC) curve was used to identify the cutoff value of PNI. Results: A total of 858 TCPs were eligible and included, the median age was 62 years (range: 18–107). The most common primary cancer sites were colorectal cancer in 151 patients (17.6%), hepatobiliary in 129 (15%), lung cancer in 115 (13.4%), breast cancer in 114 (13.3%), and genitourinary in 80 (9.3%). The mean value of PNI for all cancer types was 32.9 ± 6.7. The values showed different levels across cancer types. For patients who lived >2 weeks, PNI was 36.7 compared with that who died within 2 weeks was 29.3, which was a statistically significant (P < 0.001). By the ROC curve, the cutoff value of PNI was 32.3 and area under the curve was 0.888. The sensitivity, specificity, positive predictive value, and negative predictive value were 91.28% (95% confidence interval [CI]: 88.2–93.8), 71.09% (95% CI: 66.5–75.4), 76.5% (95% CI: 73.7–79.2), and 88.8% (95% CI: 85.3–91.5), respectively. Conclusion: The PNI is an easy and an applicable biomarker to estimate life expectancy in TCPs.
   
     
 
       

Author Related Publications

  • Amarallah Abdelmoneim Mohamed Sayed, "Myelodysplastic syndrome from theoretical review to clinical application view", PAGEPress, Italy, 2018 More
  • Amarallah Abdelmoneim Mohamed Sayed, "Patterns of Inpatient Admissions during Haj Clinical conditions, length of stay and patient outcomes at an advanced care centre in Makkah, Saudi Arabia", Pak J Med Sci, 2018 More
  • Amarallah Abdelmoneim Mohamed Sayed, "Neoadjuvant Platinum and Gemcitabine Regimens Precede Definitive Radiotherapy in Locally Advanced Bladder Cancer", Symbiosis, 2019 More
  • Amarallah Abdelmoneim Mohamed Sayed, "Efficacy and Safety of First-Line Pazopanib in Patients with Metastatic Renal Cell Carcinoma: Real-Life Multi Institutional Experience", Remedy Publications LLC, 2019 More
  • Amarallah Abdelmoneim Mohamed Sayed, "?Aggressive Care at the End of Life; Where Are We", Wolters Kluwer - Medknow, 2019 More

Department Related Publications

  • Amarallah Abdelmoneim Mohamed Sayed, "Triple Primary Carcinomas: Prostatic Adenocarcinoma, Bladder Urethral Carcinoma and Papillary Thyroid Carcinoma: A Case Report", www.ivyunion.org, 2015 More
  • Amarallah Abdelmoneim Mohamed Sayed, "CDK4/6 inhibitors in advanced breast cancer, what is beyond?", PAGEPress, Italy, 2019 More
  • Tarek Ali Mohamed Elgohary, "The Rate of Extended-Spectrum B-Lactamases among Commonly Isolated Enterobacteriaceae in Cancer Patients in Zagazig University Hospitals. معدل ال. بي-لاكتاميزيز ذات الطيف الممتد بين الطفيليات المعوية الشائعة في مرضى السرطان في مستشفيات جامعة الزقازيق", Journal of Microbiology Research (2017) 7(2): 31-38, 2017 More
  • Tarek Ali Mohamed Elgohary, "Clinical and Pathological Value of MACC-1 Expression in Gastric Carcinoma. القيمة السريرية والمرضية لتعبير (MACC-1) في سرطان المعدة", Journal of Cancer Therapy (2019) 10(7), 609-618, 2019 More
  • Rasha Mohamed Mostafa Hagag, "Ultrasound elastography in pathological enlarged cervical lymph nodes compared to histopathology. Egyptian Journal of Radiology and Nuclear Medicine", Egyptian Journal of Radiology and Nuclear Medicine •, 2016 More
Tweet